ISN Frontiers Webinar: New insights into clinical management of C3G
The drugs that are currently used, such as corticosteroids and immunosuppressants, are frequently ineffective in C3G . Eculizumab, an anti-C5 monoclonal antibody, has been used occasionally however, only a few patients have achieved remission. This heterogeneous response could be related to the extent of terminal complement activation. The webinar will focus on drugs that target the complement system at different levels and are under investigation for C3G . Clinical trials to test new therapeutics will be challenging and heavily influenced by the heterogeneity of this disease. This creates the need to characterize each patient to match the specific complement abnormality with the type of intervention.
- The complement system and its role in C3G
- Personalized clinical management of patients
- Preliminary results of clinical trial with complement inhibitors
- New therapeutic perspectives.
We are delighted at the immense interest in the ISN Frontiers webinar series and topics. In appreciation of this interest, the ISN and the Mario Negri Institute for Pharmacological Research are pleased to inform you that all attendees of the ISN Frontiers webinar will be offered a 10% registration discount to the Frontiers event in Bergamo on June 23-25, 2022.
Supported by an educational grant from Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease
Supported by Novartis